PDCD1 and cancer: PD-1 checkpoint inhibition to activate systemic immune responses has rapidly emerged as a critical tool in the cancer therapy arsenal, with considerable effort dedicated to understanding the underlying beneficial mechanisms, including enhancement of T-cell priming and activation and reinvigoration of exhausted intra-tumoral T-cells (Pauken and Wherry 2015; Oh et al. 2020).